ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Interim 2025/26 influenza vaccine effectiveness estimates with immuno-epidemiological considerations for A(H3N2) subclade K protection, Canada, January 2026.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Reduced T cell epitope cross-conservation and immunogenic potential is associated with emergence of a dominant influenza subclade K in 2025.Human vaccines & immunotherapeutics · 2026Article
- Effectiveness of the 2025-2026 seasonal influenza vaccine among U.S. veterans: an observational study.EClinicalMedicine · 2026Article
- Near real-time data on the human neutralizing antibody landscape to influenza virus in summer of 2026 shows antigenic advance of H3N2 subclade K region D mutants and H1N1 D.3.1.1 Sa mutants.bioRxiv : the preprint server for biology · 2026Article
- Host cell entry and neutralisation sensitivity of H3N2 influenza A virus subclade K.NPJ vaccines · 2026Article
- Article
- Early circulation of influenza A(H3N2) subclade K: antigenic drift and vaccine effectiveness.Osong public health and research perspectives · 2026Article
- Seasonal vaccine-induced immunity shows preserved cross-reactivity to H3N2 subclade K in adults.EBioMedicine · 2026Article
- Interim 2025/26 LP.8.1 vaccine effectiveness estimates against COVID-19 from the Canadian Sentinel Practitioner Surveillance Network (SPSN): insights into possible impact of influenza and other respiratory virus co-circulation.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Influenza A(H3N2) Subclade K (J.2.4.1): Molecular Characterization, Antigenic Divergence, and Global Spread During the 2025/26 Season.Infectious disease reports · 2026Article
- Influenza Antibody Levels Associated with Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu VE Network, November 2018-May 2019.medRxiv : the preprint server for health sciences · 2026Article
- Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026.MMWR. Morbidity and mortality weekly report · 2026Article
- Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026.MMWR. Morbidity and mortality weekly report · 2026Article
- Mapping the specificity of H3N2 strain-specific and cross-reactive human neutralizing antibodies elicited by the 2025-2026 influenza vaccine.medRxiv : the preprint server for health sciences · 2026Article
- Near real-time data on the human neutralizing antibody landscape to influenza virus as of early 2026 to inform vaccine-strain selection.bioRxiv : the preprint server for biology · 2026Article
- Seasonal vaccine-induced immunity shows preserved cross-reactivity to H3N2 subclade K in adults.medRxiv : the preprint server for health sciences · 2026Article
- Reduced neutralising antibody responses against emerging 2025/26 influenza A(H1N1)pdm09 subclade D.3.1 and A(H3N2) subclade K viruses among healthcare workers, Finland, August to October 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Influenza vaccine effectiveness from nine studies during drifted A(H3N2) subclade K predominance, Europe, September 2025 to January 2026.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Influenza A(H3N2) subclade K (J.2.4.1) viruses associated with a surge at a university health clinic, Arizona, the United States, November to early December 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Modest protection from vaccination against influenza A(H3N2) subclade K, Beijing, China, 2025/26 season.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Near real-time data on the human neutralizing antibody landscape to influenza virus as of early 2026 to inform vaccine-strain selection.Virus evolution · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In interim 2025/26 analyses, the Canadian Sentinel Practitioner Surveillance Network estimates influenza vaccine reduced the risk of medically-attended acute respiratory illness due to predominant influenza A(H3N2) viruses, including antigenically distinct subclade K, by about 40% relative to unvaccinated individuals. Vaccine effectiveness was about 30% against A(H1N1)pdm09, with insufficient case numbers for interim influenza B estimation. Meaningful protection against subclade K, despite substantial vaccine mismatch, is interpreted in the context of immuno-epidemiological considerations, including potential viral glycosylation, imprinting, and pre-immunity effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.